Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is prioritizing in-vivo gene editing therapy programs targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in H1 and mid-2026, respectively. These new programs use in-vivo LNP delivery, target larger markets, and could provide substantially better advantages for PRME over ex-vivo gene editing.
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.
14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
9 May 2025 Date | | - Cons. EPS | - EPS |
28 Feb 2025 Date | | - Cons. EPS | - EPS |
13 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
9 May 2025 Date | | - Cons. EPS | - EPS |
28 Feb 2025 Date | | - Cons. EPS | - EPS |
13 Nov 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Jeremy S. Duffield CEO | NASDAQ (NMS) Exchange | 74168J101 Cusip |
US Country | 214 Employees | - Last Dividend | - Last Split | 20 Oct 2022 IPO Date |
Prime Medicine, Inc. is a biotechnology enterprise specialized in pioneering genetic therapies to combat a broad spectrum of diseases by harnessing the power of gene editing technology. Established in 2019, the company positions itself at the forefront of genetic medicine with its innovative approach to editing DNA sequences. Operating from its headquarters in Cambridge, Massachusetts, Prime Medicine is dedicated to realizing the potential of genetic correction and modification to treat conditions that have long been considered untreatable. The company has embarked on a significant collaboration with Cimeio Therapeutics, focusing on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs, targeting genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
At the core of Prime Medicine's offerings are the Prime Editors, a revolutionary gene editing tool. This technology combines a Prime Editor protein, which is a fusion of a Cas protein and a reverse transcriptase enzyme, with a pegRNA (prime editing guide RNA). The pegRNA is crucial as it not only directs the Prime Editor to a specific location within the genome but also supplies the template needed for executing the desired edit on the target DNA sequence. This sophisticated mechanism allows for precision in gene editing, paving the way for treatment strategies that could correct genetic mutations at their source.
Underpinning Prime Medicine's innovative technology is its strategic research collaboration with Cimeio Therapeutics. This partnership is primarily focused on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs. These novel therapeutic strategies are designed to treat a range of conditions, from genetic diseases to cancers like acute myeloid leukemia and myelodysplastic syndrome. This collaboration highlights Prime Medicine's commitment to leveraging its technology in concert with other biotech entities to address complex medical challenges.